Efficacy of pentosan polysulfate in <i>in vitro</i> models of lysosomal storage disorders: Fabry and Gaucher Disease
- Autores
- Crivaro, Andrea Natalia; Mucci, Juan Marcos; Bondar, Constanza María; Ormazabal, Maximiliano Emanuel; Ceci, Romina; Simonaro, Calogera; Rozenfeld, Paula Adriana
- Año de publicación
- 2019
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Gaucher and Fabry diseases are the most prevalent sphingolipidoses. Chronic inflammation is activated in those disorders, which could play a role in pathogenesis. Significant degrees of amelioration occur in patients upon introduction of specific therapies; however, restoration to complete health status is not always achieved. The idea of an adjunctive therapy that targets inflammation may be a suitable option for patients. PPS is a mixture of semisynthetic sulfated polyanions that have been shown to have anti-inflammatory effects in mucopolysaccharidosis type I and II patients and animal models of type I, IIIA and VI. We hypothesized PPS could be a useful adjunctive therapy to inflammation for Gaucher and Fabry diseases. The objective of this work is to analyze the in vitro effect of PPS on inflammatory cytokines in cellular models of Gaucher and Fabry diseases, and to study its effect in Gaucher disease associated in vitro bone alterations. Cultures of peripheral blood mononuclear cells from Fabry and Gaucher patients were exposed to PPS. The secretion of proinflammatory cytokines was significantly reduced. Peripheral blood cells exposed to PPS from Gaucher patients revealed a reduced tendency to differentiate to osteoclasts. Osteoblasts and osteocytes cell lines were incubated with an inhibitor of glucocerebrosidase, and conditioned media was harvested in order to analyze if those cells secrete factors that induce osteoclastogenesis. Conditioned media from this cell cultures exposed to PPS produced lower numbers of osteoclasts. We could demonstrate PPS is an effective molecule to reduce the production of proinflammatory cytokines in in vitro models of Fabry and Gaucher diseases. Moreover, it was effective at ameliorating bone alterations of in vitro models of Gaucher disease. These results serve as preclinical supportive data to start clinical trials in human patients to analyze the effect of PPS as a potential adjunctive therapy for Fabry and Gaucher diseases.
Facultad de Ciencias Exactas
Instituto de Estudios Inmunológicos y Fisiopatológicos - Materia
-
Ciencias Exactas
Gaucher's disease
cytokines
inflammatory diseases
osteoclasts
cytokine therapy
lysosomes
osteoblasts
Fabry disease - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- http://creativecommons.org/licenses/by/4.0/
- Repositorio
- Institución
- Universidad Nacional de La Plata
- OAI Identificador
- oai:sedici.unlp.edu.ar:10915/107850
Ver los metadatos del registro completo
id |
SEDICI_35dc385efca9e42bc42f3961c76a882e |
---|---|
oai_identifier_str |
oai:sedici.unlp.edu.ar:10915/107850 |
network_acronym_str |
SEDICI |
repository_id_str |
1329 |
network_name_str |
SEDICI (UNLP) |
spelling |
Efficacy of pentosan polysulfate in <i>in vitro</i> models of lysosomal storage disorders: Fabry and Gaucher DiseaseCrivaro, Andrea NataliaMucci, Juan MarcosBondar, Constanza MaríaOrmazabal, Maximiliano EmanuelCeci, RominaSimonaro, CalogeraRozenfeld, Paula AdrianaCiencias ExactasGaucher's diseasecytokinesinflammatory diseasesosteoclastscytokine therapylysosomesosteoblastsFabry diseaseGaucher and Fabry diseases are the most prevalent sphingolipidoses. Chronic inflammation is activated in those disorders, which could play a role in pathogenesis. Significant degrees of amelioration occur in patients upon introduction of specific therapies; however, restoration to complete health status is not always achieved. The idea of an adjunctive therapy that targets inflammation may be a suitable option for patients. PPS is a mixture of semisynthetic sulfated polyanions that have been shown to have anti-inflammatory effects in mucopolysaccharidosis type I and II patients and animal models of type I, IIIA and VI. We hypothesized PPS could be a useful adjunctive therapy to inflammation for Gaucher and Fabry diseases. The objective of this work is to analyze the <i>in vitro</i> effect of PPS on inflammatory cytokines in cellular models of Gaucher and Fabry diseases, and to study its effect in Gaucher disease associated <i>in vitro</i> bone alterations. Cultures of peripheral blood mononuclear cells from Fabry and Gaucher patients were exposed to PPS. The secretion of proinflammatory cytokines was significantly reduced. Peripheral blood cells exposed to PPS from Gaucher patients revealed a reduced tendency to differentiate to osteoclasts. Osteoblasts and osteocytes cell lines were incubated with an inhibitor of glucocerebrosidase, and conditioned media was harvested in order to analyze if those cells secrete factors that induce osteoclastogenesis. Conditioned media from this cell cultures exposed to PPS produced lower numbers of osteoclasts. We could demonstrate PPS is an effective molecule to reduce the production of proinflammatory cytokines in <i>in vitro</i> models of Fabry and Gaucher diseases. Moreover, it was effective at ameliorating bone alterations of <i>in vitro</i> models of Gaucher disease. These results serve as preclinical supportive data to start clinical trials in human patients to analyze the effect of PPS as a potential adjunctive therapy for Fabry and Gaucher diseases.Facultad de Ciencias ExactasInstituto de Estudios Inmunológicos y Fisiopatológicos2019info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArticulohttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfhttp://sedici.unlp.edu.ar/handle/10915/107850enginfo:eu-repo/semantics/altIdentifier/url/http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC6544267&blobtype=pdfinfo:eu-repo/semantics/altIdentifier/url/https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0217780info:eu-repo/semantics/altIdentifier/issn/1932-6203info:eu-repo/semantics/altIdentifier/pmid/31150494info:eu-repo/semantics/altIdentifier/doi/10.1371/journal.pone.0217780info:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by/4.0/Creative Commons Attribution 4.0 International (CC BY 4.0)reponame:SEDICI (UNLP)instname:Universidad Nacional de La Platainstacron:UNLP2025-10-15T11:15:46Zoai:sedici.unlp.edu.ar:10915/107850Institucionalhttp://sedici.unlp.edu.ar/Universidad públicaNo correspondehttp://sedici.unlp.edu.ar/oai/snrdalira@sedici.unlp.edu.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:13292025-10-15 11:15:46.719SEDICI (UNLP) - Universidad Nacional de La Platafalse |
dc.title.none.fl_str_mv |
Efficacy of pentosan polysulfate in <i>in vitro</i> models of lysosomal storage disorders: Fabry and Gaucher Disease |
title |
Efficacy of pentosan polysulfate in <i>in vitro</i> models of lysosomal storage disorders: Fabry and Gaucher Disease |
spellingShingle |
Efficacy of pentosan polysulfate in <i>in vitro</i> models of lysosomal storage disorders: Fabry and Gaucher Disease Crivaro, Andrea Natalia Ciencias Exactas Gaucher's disease cytokines inflammatory diseases osteoclasts cytokine therapy lysosomes osteoblasts Fabry disease |
title_short |
Efficacy of pentosan polysulfate in <i>in vitro</i> models of lysosomal storage disorders: Fabry and Gaucher Disease |
title_full |
Efficacy of pentosan polysulfate in <i>in vitro</i> models of lysosomal storage disorders: Fabry and Gaucher Disease |
title_fullStr |
Efficacy of pentosan polysulfate in <i>in vitro</i> models of lysosomal storage disorders: Fabry and Gaucher Disease |
title_full_unstemmed |
Efficacy of pentosan polysulfate in <i>in vitro</i> models of lysosomal storage disorders: Fabry and Gaucher Disease |
title_sort |
Efficacy of pentosan polysulfate in <i>in vitro</i> models of lysosomal storage disorders: Fabry and Gaucher Disease |
dc.creator.none.fl_str_mv |
Crivaro, Andrea Natalia Mucci, Juan Marcos Bondar, Constanza María Ormazabal, Maximiliano Emanuel Ceci, Romina Simonaro, Calogera Rozenfeld, Paula Adriana |
author |
Crivaro, Andrea Natalia |
author_facet |
Crivaro, Andrea Natalia Mucci, Juan Marcos Bondar, Constanza María Ormazabal, Maximiliano Emanuel Ceci, Romina Simonaro, Calogera Rozenfeld, Paula Adriana |
author_role |
author |
author2 |
Mucci, Juan Marcos Bondar, Constanza María Ormazabal, Maximiliano Emanuel Ceci, Romina Simonaro, Calogera Rozenfeld, Paula Adriana |
author2_role |
author author author author author author |
dc.subject.none.fl_str_mv |
Ciencias Exactas Gaucher's disease cytokines inflammatory diseases osteoclasts cytokine therapy lysosomes osteoblasts Fabry disease |
topic |
Ciencias Exactas Gaucher's disease cytokines inflammatory diseases osteoclasts cytokine therapy lysosomes osteoblasts Fabry disease |
dc.description.none.fl_txt_mv |
Gaucher and Fabry diseases are the most prevalent sphingolipidoses. Chronic inflammation is activated in those disorders, which could play a role in pathogenesis. Significant degrees of amelioration occur in patients upon introduction of specific therapies; however, restoration to complete health status is not always achieved. The idea of an adjunctive therapy that targets inflammation may be a suitable option for patients. PPS is a mixture of semisynthetic sulfated polyanions that have been shown to have anti-inflammatory effects in mucopolysaccharidosis type I and II patients and animal models of type I, IIIA and VI. We hypothesized PPS could be a useful adjunctive therapy to inflammation for Gaucher and Fabry diseases. The objective of this work is to analyze the <i>in vitro</i> effect of PPS on inflammatory cytokines in cellular models of Gaucher and Fabry diseases, and to study its effect in Gaucher disease associated <i>in vitro</i> bone alterations. Cultures of peripheral blood mononuclear cells from Fabry and Gaucher patients were exposed to PPS. The secretion of proinflammatory cytokines was significantly reduced. Peripheral blood cells exposed to PPS from Gaucher patients revealed a reduced tendency to differentiate to osteoclasts. Osteoblasts and osteocytes cell lines were incubated with an inhibitor of glucocerebrosidase, and conditioned media was harvested in order to analyze if those cells secrete factors that induce osteoclastogenesis. Conditioned media from this cell cultures exposed to PPS produced lower numbers of osteoclasts. We could demonstrate PPS is an effective molecule to reduce the production of proinflammatory cytokines in <i>in vitro</i> models of Fabry and Gaucher diseases. Moreover, it was effective at ameliorating bone alterations of <i>in vitro</i> models of Gaucher disease. These results serve as preclinical supportive data to start clinical trials in human patients to analyze the effect of PPS as a potential adjunctive therapy for Fabry and Gaucher diseases. Facultad de Ciencias Exactas Instituto de Estudios Inmunológicos y Fisiopatológicos |
description |
Gaucher and Fabry diseases are the most prevalent sphingolipidoses. Chronic inflammation is activated in those disorders, which could play a role in pathogenesis. Significant degrees of amelioration occur in patients upon introduction of specific therapies; however, restoration to complete health status is not always achieved. The idea of an adjunctive therapy that targets inflammation may be a suitable option for patients. PPS is a mixture of semisynthetic sulfated polyanions that have been shown to have anti-inflammatory effects in mucopolysaccharidosis type I and II patients and animal models of type I, IIIA and VI. We hypothesized PPS could be a useful adjunctive therapy to inflammation for Gaucher and Fabry diseases. The objective of this work is to analyze the <i>in vitro</i> effect of PPS on inflammatory cytokines in cellular models of Gaucher and Fabry diseases, and to study its effect in Gaucher disease associated <i>in vitro</i> bone alterations. Cultures of peripheral blood mononuclear cells from Fabry and Gaucher patients were exposed to PPS. The secretion of proinflammatory cytokines was significantly reduced. Peripheral blood cells exposed to PPS from Gaucher patients revealed a reduced tendency to differentiate to osteoclasts. Osteoblasts and osteocytes cell lines were incubated with an inhibitor of glucocerebrosidase, and conditioned media was harvested in order to analyze if those cells secrete factors that induce osteoclastogenesis. Conditioned media from this cell cultures exposed to PPS produced lower numbers of osteoclasts. We could demonstrate PPS is an effective molecule to reduce the production of proinflammatory cytokines in <i>in vitro</i> models of Fabry and Gaucher diseases. Moreover, it was effective at ameliorating bone alterations of <i>in vitro</i> models of Gaucher disease. These results serve as preclinical supportive data to start clinical trials in human patients to analyze the effect of PPS as a potential adjunctive therapy for Fabry and Gaucher diseases. |
publishDate |
2019 |
dc.date.none.fl_str_mv |
2019 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Articulo http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://sedici.unlp.edu.ar/handle/10915/107850 |
url |
http://sedici.unlp.edu.ar/handle/10915/107850 |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/url/http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC6544267&blobtype=pdf info:eu-repo/semantics/altIdentifier/url/https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0217780 info:eu-repo/semantics/altIdentifier/issn/1932-6203 info:eu-repo/semantics/altIdentifier/pmid/31150494 info:eu-repo/semantics/altIdentifier/doi/10.1371/journal.pone.0217780 |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by/4.0/ Creative Commons Attribution 4.0 International (CC BY 4.0) |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
http://creativecommons.org/licenses/by/4.0/ Creative Commons Attribution 4.0 International (CC BY 4.0) |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
reponame:SEDICI (UNLP) instname:Universidad Nacional de La Plata instacron:UNLP |
reponame_str |
SEDICI (UNLP) |
collection |
SEDICI (UNLP) |
instname_str |
Universidad Nacional de La Plata |
instacron_str |
UNLP |
institution |
UNLP |
repository.name.fl_str_mv |
SEDICI (UNLP) - Universidad Nacional de La Plata |
repository.mail.fl_str_mv |
alira@sedici.unlp.edu.ar |
_version_ |
1846064215514677248 |
score |
13.22299 |